Diabetic kidney disease (DKD), a deleterious complication of diabetes, is one of the major causes of chronic kidney disease and is recognized as a public health problem worldwide. Importantly, with the increasing incidence of Type 2 Diabetes Miletus(T2DM), the frequency of DKD has also increased. These patients are often complicated with cardiovascular and neurological diseases and characterized by higher risk of end-stage renal disease (ESRD) progression, which increases patients’ mortality and social burden.
Translational studies on DKD, involving risk factors, drug effectiveness, efficacy of treatment schemes, prognosis analysis, disease differentiation, etc., provide guidance for the in-depth understanding of DKD in clinics. The pathogenic mechanism of DKD is still unclear. Recent studies indicated that immune response stimulated by gut microbiota dysbiosis is one of the most characteristic changes of DKD. Gut microbiota participates in the development of DKD through disturbing immune system, forming a gut-microbiome-immune axis. Gut microbiota and their derived metabolites can pass through intestinal epithelium and be recognized by immune system. However, the relationship between immunity and DKD remains to be elucidated, the details remain to be further revealed.
This Research Topic includes, but is by no means limited to the following subtopics:
1)how the microbiota affects the progression of DKD;
2)the influence of immune therapy and microbiota intervention on DKD progression;
3)translational study based on gut microbiota, immunity and DKD;
4)observational research on DKD, including etiology prediction, correlation analysis of clinical indicators, prognosis analysis, etc.
This Research Topic welcomes contributions from original research, systematic review, methods, review and mini review to policy and practice reviews, hypothesis and theory, perspective, conceptual analysis, data report, policy brief, brief research report, general commentary, and opinion.
Diabetic kidney disease (DKD), a deleterious complication of diabetes, is one of the major causes of chronic kidney disease and is recognized as a public health problem worldwide. Importantly, with the increasing incidence of Type 2 Diabetes Miletus(T2DM), the frequency of DKD has also increased. These patients are often complicated with cardiovascular and neurological diseases and characterized by higher risk of end-stage renal disease (ESRD) progression, which increases patients’ mortality and social burden.
Translational studies on DKD, involving risk factors, drug effectiveness, efficacy of treatment schemes, prognosis analysis, disease differentiation, etc., provide guidance for the in-depth understanding of DKD in clinics. The pathogenic mechanism of DKD is still unclear. Recent studies indicated that immune response stimulated by gut microbiota dysbiosis is one of the most characteristic changes of DKD. Gut microbiota participates in the development of DKD through disturbing immune system, forming a gut-microbiome-immune axis. Gut microbiota and their derived metabolites can pass through intestinal epithelium and be recognized by immune system. However, the relationship between immunity and DKD remains to be elucidated, the details remain to be further revealed.
This Research Topic includes, but is by no means limited to the following subtopics:
1)how the microbiota affects the progression of DKD;
2)the influence of immune therapy and microbiota intervention on DKD progression;
3)translational study based on gut microbiota, immunity and DKD;
4)observational research on DKD, including etiology prediction, correlation analysis of clinical indicators, prognosis analysis, etc.
This Research Topic welcomes contributions from original research, systematic review, methods, review and mini review to policy and practice reviews, hypothesis and theory, perspective, conceptual analysis, data report, policy brief, brief research report, general commentary, and opinion.
